Payment overview · 2025
General Payments
$922.74
23 reported records · 11 companies
Healthcare provider profile · identity verified
Karen Larsen, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · OCALA, FL · NPI 1154762409
Verified facts
What the public records show
CMS Open Payments records show Karen Larsen, ARNP received $922.74 in general payments during 2025 across 23 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 133 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $177.98 | 19.3% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $149.93 | 16.2% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $136.96 | 14.8% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $109.83 | 11.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $94.50 | 10.2% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $92.78 | 10.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $73.09 | 7.9% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $37.21 | 4.0% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.42 | 2.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.87 | 1.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $12.17 | 1.3% | 4 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $837.75 | 22 |
| Education | $84.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $177.98 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $149.93 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $136.96 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $92.78 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $73.09 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $73.09 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $57.60 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $37.21 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $36.90 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $36.90 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.84 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $12.17 | 4 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 102 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 133 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
57 | 17 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
78 | 22 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
133 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 740 | 245 |
| Levothyroxine Sodium | Levothyroxine Sodium | 582 | 161 |
| Losartan Potassium | Losartan Potassium | 369 | 111 |
| Amlodipine Besylate | Amlodipine Besylate | 354 | 110 |
| Lisinopril | Lisinopril | 311 | 95 |
| Omeprazole | Omeprazole | 300 | 95 |
| Simvastatin | Simvastatin | 249 | 70 |
| Gabapentin | Gabapentin | 240 | 83 |
| Metformin Hcl | Metformin Hcl | 225 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 213 | 72 |
| Metformin Hcl Er | Metformin Hcl | 209 | 67 |
| Alprazolam | Alprazolam | 198 | 41 |
| Sertraline Hcl | Sertraline Hcl | 181 | 58 |
| Trazodone Hcl | Trazodone Hcl | 178 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 174 | 50 |
| Tramadol Hcl | Tramadol Hcl | 148 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 141 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 38 |
| Ozempic | Semaglutide | 133 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 132 | 38 |
| Carvedilol | Carvedilol | 128 | 33 |
| Meloxicam | Meloxicam | 124 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 120 | 39 |
| Cephalexin | Cephalexin | 117 | 81 |
| Buspirone Hcl | Buspirone Hcl | 115 | 36 |
| Famotidine | Famotidine | 109 | 36 |
| Glimepiride | Glimepiride | 109 | 36 |
| Clonazepam | Clonazepam | 104 | 14 |
| Jardiance | Empagliflozin | 102 | 27 |
| Methylprednisolone | Methylprednisolone | 98 | 77 |
| Pioglitazone Hcl | Pioglitazone Hcl | 95 | 29 |
| Valsartan | Valsartan | 93 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 92 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 26 |
| Azithromycin | Azithromycin | 85 | 75 |
| Bupropion Xl | Bupropion Hcl | 85 | 25 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 12 |
| Ezetimibe | Ezetimibe | 83 | 29 |
| Montelukast Sodium | Montelukast Sodium | 82 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 79 | 60 |
| Furosemide | Furosemide | 79 | 33 |
| Farxiga | Dapagliflozin Propanediol | 78 | 22 |
| Potassium Chloride | Potassium Chloride | 73 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 70 | 24 |
| Alendronate Sodium | Alendronate Sodium | 63 | 26 |
| Allopurinol | Allopurinol | 63 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 61 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 22 |
| Synthroid | Levothyroxine Sodium | 57 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 56 | 42 |
| Baclofen | Baclofen | 55 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 53 | 12 |
| Atenolol | Atenolol | 52 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 47 | 15 |
| Sumatriptan Succinate | Sumatriptan Succinate | 47 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 13 |
| Estradiol | Estradiol | 45 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 45 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 45 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 16 |
| Eszopiclone | Eszopiclone | 41 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 12 |
| Temazepam | Temazepam | 41 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 40 | 15 |
| Eliquis | Apixaban | 35 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 33 | 13 |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | 24 |
| Meclizine Hcl | Meclizine Hcl | 32 | 20 |
| Prednisone | Prednisone | 32 | 22 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | 14 |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Lorazepam | Lorazepam | 29 | 17 |
| Azelastine Hcl | Azelastine Hcl | 28 | 15 |
| Nystatin | Nystatin | 28 | 20 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 25 |
| Celecoxib | Celecoxib | 27 | suppressed |
| Ibuprofen | Ibuprofen | 27 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Glipizide | Glipizide | 25 | suppressed |
| Lovastatin | Lovastatin | 25 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 25 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 17 |
| Aripiprazole | Aripiprazole | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 16 |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | 16 |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 16 |
| Spironolactone | Spironolactone | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 16 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Gemtesa | Vibegron | 14 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Repatha Syringe | Evolocumab | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $922.74 · 23 records | AstraZeneca Pharmaceuticals LP | BREZTRI, Cologuard Collection Kit, JARDIANCE, MOUNJARO, Ozempic, QULIPTA, REPATHA, Rybelsus, SAPIEN 3 Ultra RESILIA, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, WATCHMAN FLX, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error